Evidence map›Paper›PMID 33514658›Full record

ArticleMolecular cancer research : MCR2021

Selective ERBB2 and BCL2 Inhibition Is Synergistic for Mitochondrial-Mediated Apoptosis in MDS and AML Cells.

Angel Y F Kam, Sadhna O Piryani, Chang-Lung Lee, David A Rizzieri, Neil L Spector, Stefanie Sarantopoulos, Phuong L Doan

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular cancer research : MCR, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Angel Y F KamDivision of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University, Durham, North Carolina.
Sadhna O PiryaniDivision of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University, Durham, North Carolina.
Chang-Lung LeeDepartment of Radiation Oncology, Duke University Medical Center, Durham, North Carolina.ORCID 0000-0002-0673-633X
David A RizzieriDivision of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University, Durham, North Carolina.
Neil L SpectorDuke Cancer Institute, Duke University, Durham, North Carolina.
Stefanie SarantopoulosDivision of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University, Durham, North Carolina.
Phuong L DoanDivision of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University, Durham, North Carolina. Phuong.Doan@duke.edu.ORCID 0000-0003-1361-2068
Duke University · US

Funding

Ionizing radiation promotes clonal expansion of premalignant cells in the thymusR00CA212198 · NCI · DUKE UNIVERSITY · PI LEE, CHANG-LUNG · 2018 to 2020
$747k
Role of ErbB receptor signaling in regulating normal and leukemic stem cell fateK08CA184552 · NCI · DUKE UNIVERSITY · PI DOAN, PHUONG LINH · 2014 to 2018
$639k
NCI NIH HHS K08 CA184552NCI NIH HHS R00 CA212198
6 · The paper itself

Abstract

The

Indexed as

AnimalsApoptosisErb-b2 Receptor Tyrosine KinasesHumansLeukemia, Myeloid, AcuteMyelodysplastic SyndromesProto-Oncogene Proteins c-bcl-2BCL2 protein, humanERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesProto-Oncogene Proteins c-bcl-2

Identifiers

PMID33514658
PMCPMC8137592
OpenAlexW3122920598

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.